Technetium Tc-99m pertechnetate
Explore a selection of our essential drug information below, or:
Identification
- Summary
Technetium Tc-99m pertechnetate is a radiocontrast agent used for the identification of various organs, including but not limited to the brain, thyroid, placenta, and bladder.
- Generic Name
- Technetium Tc-99m pertechnetate
- DrugBank Accession Number
- DB09314
- Background
Technetium Tc-99m pertechnetate is a radiopharmaceutical diagnostic agent composed of an oxoanion with the chemical formula TcO4-. Pertechnetate has a wide variety of uses within nuclear medicine as it distributes within the body to a similar extent as iodine. It also concentrates in the thyroid gland, salivary glands, gastric mucosa, and choroid plexus. However, in contrast to the iodide ion, the pertechnetate ion is released unchanged from the thyroid gland. Currently marketed as the product Drytec, technetium-99m pertechnetate is indicated for imaging of the following tissues: thyroid, salivary gland, urinary bladder (for detection of vesico-ureteral reflux), and the nasolacrimal drainage system.
Technetium-99m's short half life (6 hours) makes storage impossible, therefore it is supplied as its parent nuclide molybdenum-99, which spontaneously decays to technetium-99 through beta decay. This is normally supplied in a hospital setting through the use of a technetium-99m generator, whereby technetium exits the generator in the form of the pertechnetate ion, TcO4−, which can be extracted and promptly used for clinical diagnostics. Following intravenous injection, single photon emission computed tomography (SPECT) is performed to detect the gamma ray emmitted by the decay of Technetium-99m to Technetium-99.
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Structure
- Weight
- Average: 169.968
Monoisotopic: 169.95002301 - Chemical Formula
- H8O4Tc
- Synonyms
- (99Tc)pertechnetate
- CPERT
- GPERT
- Pertechnetate-99Tc
- Technetium (99mTc) Pertechnetate
- Technetium Tc 99m Pertechnetate
Pharmacology
- Indication
Sodium Pertechnetate Tc99m Injection is indicated for use in adults for imaging in the following tissues: thyroid, salivary gland, urinary bladder (for detection of vesico-ureteral reflux), and nasolacrimal drainage system (dacryoscintigraphy). It is indicated for use in children for imaging the following tissues: thyroid and urinary bladder.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Diagnostic agent Vesico-ureteral reflux •••••••••••• •••••• ••••••••• - Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
The pertechnetate ion distributes in the body similarly to the iodide ion, but is not organified when trapped in the thyroid gland. It also concentrates in the thyroid gland, salivary glands, gastric mucosa, and choroid plexus. However, in contrast to the iodide ion, the pertechnetate ion is released unchanged from the thyroid gland.
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- No interactions found.
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Product Ingredients
Ingredient UNII CAS InChI Key Technetium Tc-99m sodium pertechnetate A0730CX801 23288-60-0 MKADDTFVKFMZGF-UHFFFAOYSA-N - Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Drytec (Technetium Tc99m Generator) Generator 338 mCi/1mL Intravascular Medi-Physics Inc. 2014-04-01 2019-01-10 US Drytec (Technetium Tc99m Generator) Generator 230 mCi/1mL Intravascular Medi-Physics Inc. 2014-04-01 2019-01-10 US Drytec (Technetium Tc99m Generator) Generator 2027 mCi/1mL Intravascular Medi-Physics Inc. 2014-04-01 2019-01-10 US Drytec (Technetium Tc99m Generator) Generator 135 mCi/1mL Intravascular Medi-Physics Inc. 2014-04-01 2019-01-10 US Drytec (Technetium Tc99m Generator) Generator 1081 mCi/1mL Intravascular Medi-Physics Inc. 2014-04-01 2019-01-10 US - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image POLGENTEC 2-120 GBQ GENERADOR DE RADIONUCLEIDOS Technetium Tc-99m sodium pertechnetate (120 GBq) + Aluminum oxide (2 g) + Sodium molybdate (0 GBq) Solution Intravenous ISOMEDIX TECHNOLOGY S.A.S. 2013-09-19 Not applicable Colombia TECHNELITE® GENERADOR DE TECNECIO TC 99M Technetium Tc-99m sodium pertechnetate (0 GBq) + Sodium molybdate (740 GBq) Solution Intravenous COMERCIALIZADORA DE MATERIAL CIENTÍFICO E INDUSTRIAL S.A.S. - COMCI S.A.S. 2006-11-10 Not applicable Colombia ULTRA TECHNEKOW FM2.15 - 43.00 GBQ GENERADOR DE RADIONÚCLIDO. Technetium Tc-99m sodium pertechnetate (38.1 GBq) + Sodium chloride (9 mg) + Sodium molybdate (43 GBq) + Water (1 mL) Solution Intraocular; Intravenous Curium Netherlands B.V. 2019-03-04 Not applicable Colombia
Categories
- ATC Codes
- V09FX01 — Technetium (99mtc) pertechnetate
- Drug Categories
- Compounds used in a research, industrial, or household setting
- Diagnostic Radiopharmaceuticals
- Diagnostic Uses of Chemicals
- Indicators and Reagents
- Laboratory Chemicals
- Radioactive Diagnostic Agent
- Radiopharmaceutical Activity
- Radiopharmaceuticals
- Technetium Compounds
- Thyroid Diagnostic Radiopharmaceuticals
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- PPP8783IQ1
- CAS number
- 23288-61-1
- InChI Key
- ZTFPRNKAHXDALS-RCUQKECRSA-N
- InChI
- InChI=1S/4H2O.Tc/h4*1H2;/q;;;;-1/i;;;;1+1
- IUPAC Name
- tetrahydrate (98Tc)technetiumuide
- SMILES
- O.O.O.O.[98Tc-]
References
- General References
- Ryo UY, Vaidya PV, Schneider AB, Bekerman C, Pinsky SM: Thyroid imaging agents: a comparison of I-123 and Tc-99m pertechnetate. Radiology. 1983 Sep;148(3):819-22. [Article]
- External Links
- KEGG Drug
- D08761
- PubChem Compound
- 131709156
- PubChem Substance
- 310265199
- 1489762
- ChEMBL
- CHEMBL2109884
- RxList
- RxList Drug Page
- Wikipedia
- Pertechnetate
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data1 Active Not Recruiting Treatment Metastatic Endometrial carcinoma / Recurrent Endometrial Adenocarcinoma / Recurrent Endometrial Carcinoma / Recurrent Endometrial Clear Cell Adenocarcinoma / Recurrent Endometrial Endometrioid Adenocarcinoma / Recurrent Endometrial Mixed Cell Adenocarcinoma / Recurrent Endometrial Serous Adenocarcinoma / Recurrent Endometrial Undifferentiated Carcinoma / Recurrent Uterine Corpus Carcinosarcoma / Stage IV Uterine Corpus Cancer AJCC v7 1 somestatus stop reason just information to hide 1 Completed Diagnostic Thyroid Neoplasm 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Generator Intravascular 108 mCi/1mL Generator Intravascular 1081 mCi/1mL Generator Intravascular 135 mCi/1mL Generator Intravascular 1351 mCi/1mL Generator Intravascular 162 mCi/1mL Generator Intravascular 1622 mCi/1mL Generator Intravascular 2027 mCi/1mL Generator Intravascular 203 mCi/1mL Generator Intravascular 230 mCi/1mL Generator Intravascular 243 mCi/1mL Generator Intravascular 270 mCi/1mL Generator Intravascular 2703 mCi/1mL Generator Intravascular 338 mCi/1mL Generator Intravascular 405 mCi/1mL Generator Intravascular 541 mCi/1mL Generator Intravascular 676 mCi/1mL Generator Intravascular 68 mCi/1mL Generator Intravascular 811 mCi/1mL Solution Intravenous Solution Intravenous 10 GBq Solution Intravenous 15 GBq Solution Intravenous 17 GBq Solution Intravenous 20 GBq Solution Intravenous 25 GBq Solution Intravenous 28 GBq Solution Intravenous 31 GBq Solution Intravenous 35 GBq Solution Intravenous 40 GBq Solution Intravenous 5 GBq Solution Intravenous 50 GBq Solution Intravenous 8 GBq Injection Intravenous; Intravesical; Ophthalmic 12 Ci/12Ci Injection Intravenous; Intravesical; Ophthalmic 15 Ci/15Ci Injection Intravenous; Intravesical; Ophthalmic 19 Ci/19Ci Injection Intravenous; Intravesical; Ophthalmic 6 Ci/6Ci Injection Intravenous; Intravesical; Ophthalmic 7.5 Ci/7.5Ci Solution Intravenous 0.4 gbq Injection, solution Intravenous 250 mCi/1mL Generator Intravenous; Ophthalmic 10 GBq Generator Intravenous; Ophthalmic 12 GBq Generator Intravenous; Ophthalmic 16 GBq Generator Intravenous; Ophthalmic 2 GBq Generator Intravenous; Ophthalmic 20 GBq Generator Intravenous; Ophthalmic 25 GBq Generator Intravenous; Ophthalmic 4 GBq Generator Intravenous; Ophthalmic 50 GBq Generator Intravenous; Ophthalmic 6 GBq Generator Intravenous; Ophthalmic 8 GBq Solution Intraocular; Intravenous Injection, solution Intravenous 1 Ci/1 Injection, solution Intravenous 1.5 Ci/1 Injection, solution Intravenous 11 Ci/1 Injection, solution Intravenous 14 Ci/1 Injection, solution Intravenous 16 Ci/1 Injection, solution Intravenous 19 Ci/1 Injection, solution Intravenous 2 Ci/1 Injection, solution Intravenous 2.5 Ci/1 Injection, solution Intravenous 3 Ci/1 Injection, solution Intravenous 3.5 Ci/1 Injection, solution Intravenous 5 Ci/1 Injection, solution Intravenous 6 Ci/1 Injection, solution Intravenous 7.5 Ci/1 Generator Intravenous; Ophthalmic Solution Intravenous 3.6 mg/L - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 137.0 mg/mL ALOGPS logP -1.4 ALOGPS logP -0.65 Chemaxon logS 0.61 ALOGPS pKa (Strongest Acidic) 15.7 Chemaxon pKa (Strongest Basic) -1.8 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 1 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 25.3 Å2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 3.7 m3·mol-1 Chemaxon Polarizability 1.51 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at November 16, 2015 22:49 / Updated at October 09, 2021 02:48